Limited funding means tough choices between drug candidates. Learn how early portfolio prioritization and market access planning can maximize your pipeline's value and impact.
Selecting the right functional service provider (FSP) for safety services is fundamental to protecting patients and requires a strategic partnership that enhances trial integrity and outcomes.
Our priority is guiding promising therapies to proof-of-concept with precision and urgency, because every day saved in development matters profoundly to patients living with cancer.
Master the complexities of renal and hepatic trials by leveraging site expertise and PK modeling to navigate recruitment challenges and ensure precise dosing for impaired patient populations.
Integrated human ADME studies streamline the process from 14C synthesis to clinical conduct and final reporting to accelerate your drug development program.
